Literature DB >> 15851791

Stage II colorectal cancer: to treat or not to treat.

Patrick G Johnston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15851791     DOI： 10.1634/theoncologist.10-5-332

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  15 in total

1.  Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome.

Authors:  Amanda G Hansen; Tanner J Freeman; Shanna A Arnold; Alina Starchenko; Celestial R Jones-Paris; Michael A Gilger; Mary K Washington; Kang-Hsien Fan; Yu Shyr; Robert D Beauchamp; Andries Zijlstra
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

2.  Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer.

Authors:  Rachel C Shelton; Laura E Brotzman; Danielle M Crookes; Patrick Robles; AIfred I Neugut
Journal:  Patient Educ Couns       Date:  2018-09-17

3.  Optimal use of adjuvant chemotherapy in stage II colorectal cancer.

Authors:  Zhongguo Zhou; Xiaojun Wu; Ruojing Wang; Liren Li; Zhenhai Lu; Gong Chen; Yujing Fang; Zhizhong Pan
Journal:  Int J Colorectal Dis       Date:  2011-03-24       Impact factor: 2.571

4.  A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation.

Authors:  G Vainer; E Vainer-Mosse; A Pikarsky; S M Shenoy; F Oberman; A Yeffet; R H Singer; E Pikarsky; J K Yisraeli
Journal:  J Pathol       Date:  2008-08       Impact factor: 7.996

5.  Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Authors:  Yuqiu Jiang; Graham Casey; Ian C Lavery; Yi Zhang; Dmitri Talantov; Michelle Martin-McGreevy; Marek Skacel; Elena Manilich; Abhijit Mazumder; David Atkins; Conor P Delaney; Yixin Wang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

6.  AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

Authors:  Patrick G Johnston; Sandra Van Schaeybroeck; Philip D Dunne; Darragh G McArt; Jaine K Blayney; Murugan Kalimutho; Samanda Greer; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Maurice Loughrey; Keara Redmond; Daniel B Longley; Manuel Salto-Tellez
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

7.  CD93 gene polymorphism is associated with disseminated colorectal cancer.

Authors:  Renate S Olsen; Mikael Lindh; Emina Vorkapic; Roland E Andersson; Niklas Zar; Sture Löfgren; Jan Dimberg; Andreas Matussek; Dick Wågsäter
Journal:  Int J Colorectal Dis       Date:  2015-05-26       Impact factor: 2.571

8.  Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.

Authors:  E Letellier; M Schmitz; K Baig; N Beaume; C Schwartz; S Frasquilho; L Antunes; N Marcon; P V Nazarov; L Vallar; J Even; S Haan
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

9.  Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production.

Authors:  Pit Ullmann; Komal Qureshi-Baig; Fabien Rodriguez; Aurélien Ginolhac; Yannic Nonnenmacher; Dominik Ternes; Jil Weiler; Karoline Gäbler; Christelle Bahlawane; Karsten Hiller; Serge Haan; Elisabeth Letellier
Journal:  Oncotarget       Date:  2016-10-04

10.  Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Authors:  Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2012-08-02       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.